858 Therapeutics

Healthcare & Life Sciences

Recent Finacing

Series B

Recent Raise

$50M

858 Therapeutics is a biotechnology company developing small molecule therapeutics for oncology and immunology, with a lead asset, ETX-19477, in Phase 1 trials for advanced solid tumors.